Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Efficacy of Aflibercept (8 mg) With Sequential Laser Photocoagulation for Macular Edema Secondary to Retinal Artery Macroaneurysm: Retrospective Study"

2. november 2026 oppdatert av: Asmaa Kamel Ahmed Hassan, New Valley University

Retinal arterial macroaneurysm (RAM) is an acquired dilatation of a retinal arteriole that can rupture or leak, causing hemorrhage, exudation, macular edema, and vision loss. No standardized treatment exists, and options range from observation to laser photocoagulation, anti-VEGF therapy, or both.

Laser photocoagulation closes the aneurysm directly and stops leakage. It risks vascular occlusion, temporary worsening of exudate, and scotomas, especially in an actively leaking or edematous macula.

Anti-VEGF therapy reduces vascular permeability and exudation, improving visual acuity and central macular thickness. It does not reliably close the aneurysm itself.

High-dose aflibercept 8 mg has outperformed aflibercept 2 mg in fluid resolution, durability, and dosing interval length in neovascular AMD and diabetic macular edema (PULSAR and PHOTON trials). Its role in RAM-related macular edema, particularly as a pre-laser step to reduce edema and inflammation, has not been studied.

Study rationale: The study will test whether three monthly aflibercept 8 mg loading injections followed by targeted laser to the leaking RAM is a more effective, safer, and more durable sequential strategy than either treatment alone.

Studieoversikt

Detaljert beskrivelse

Retinal arterial macroaneurysm (RAM) is an acquired focal dilatation of a retinal arteriole, typically within the first three bifurcations, that may rupture or leak to cause hemorrhagic or exudative maculopathy with secondary macular edema and vision loss [1]. Despite its clinical significance, no standardized treatment protocol currently exists; management options range from observation to focal laser photocoagulation, anti-VEGF therapy, or a combination of both [1,2]. Laser photocoagulation directly targets the aneurysmal wall to induce closure and halt leakage, but carries risks of vascular occlusion, transient exudate worsening, and scotoma formation, particularly when applied to an actively leaking or edematous macula [2]. Anti-VEGF agents, by contrast, reduce vascular permeability and reabsorb exudation, improving visual acuity and central macular thickness, but do not reliably induce anatomical closure of the aneurysm itself [1,2].

High-dose intravitreal aflibercept 8 mg has recently demonstrated superior fluid resolution, durability, and extended dosing intervals compared with aflibercept 2 mg in neovascular age-related macular degeneration and diabetic macular edema in the pivotal PULSAR and PHOTON trials [3,4]. However, its role in RAM-associated macular edema, particularly as a pre-laser adjunct to reduce edema and inflammation before aneurysm ablation, remains unexplored.

This gap provides the rationale for the present study: to evaluate whether a loading phase of three monthly aflibercept 8 mg injections, followed by targeted laser photocoagulation of the leaking RAM site, offers a more effective, safer, and durable sequential treatment strategy for RAM-related macular edema than either modality alone

Studietype

Observasjonsmessig

Registrering (Antatt)

15

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

15 patients who were diagnosed with RAM and fulfilling study certria

Beskrivelse

1-1-Age ≥ 18 years, of either sex 2-Clinical and imaging-confirmed diagnosis of retinal arterial macroaneurysm 3-Presence of macular edema secondary to RAM involving the central subfield, with central macular thickness (CMT) > 300 µm on OCT.

4-Treatment-naïve eyes (no prior anti-VEGF injection or laser therapy for the current RAM episode).

5-Willingness and ability to comply with the monthly injection schedule and follow-up visits.

6-Signed informed consent 5-All patients were diagnosed with RAM not associated with comorbidity, such as diabetes, glaucoma

Exclusion criteria:

  1. RAM leakage site inaccessible to laser photocoagulation (e.g., juxtafoveal or subfoveal location precluding safe laser application).
  2. Significant vitreous hemorrhage precluding adequate fundus visualization or laser delivery.
  3. Known hypersensitivity to aflibercept or any component of its formulation. 4. Pregnancy or breastfeeding.

5-Systemic conditions precluding safe intravitreal injection (e.g., recent stroke or myocardial infarction within 3 months, uncontrolled thromboembolic disease).

6-Media opacity precluding adequate OCT/FFA imaging or laser treatment (e.g., dense cataract, corneal opacity).

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: RETROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in central macular thickness (CMT), measured by spectral-domain optical coherence tomography (SD-OCT), from baseline to the final follow-up visit following sequential aflibercept 8 mg loading doses and laser photocoagulation
Tidsramme: 5 mnoths

Spectral-domain optical coherence tomography (SD-OCT) Heidelberg machine: central macular thickness Best-corrected visual acuity (BCVA) is measured using the ETDRS/log MAR chart.

5 mnoths

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. januar 2027

Primær fullføring (Antatt)

1. februar 2027

Studiet fullført (Antatt)

1. mars 2027

Datoer for studieregistrering

Først innsendt

28. oktober 2026

Først innsendt som oppfylte QC-kriteriene

2. november 2026

Først lagt ut (Faktiske)

6. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere